Publication:
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Issued Date

2021-02-01

Resource Type

Article

ISSN

14765551
08876924

DOI

10.1038/s41375-020-01111-2

Other identifier(s)

2-s2.0-85099095870

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Leukemia. Vol.35, No.2 (2021), 440-453

Suggested Citation

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Slawomira Kyrcz-Krzemien, Ewa Medras, Maria Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. Vol.35, No.2 (2021), 440-453. doi:10.1038/s41375-020-01111-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76294

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Author(s)

Hagop M. Kantarjian
 Timothy P. Hughes
 Richard A. Larson
 Dong Wook Kim
 Surapol Issaragrisil
 Philipp le Coutre
 Gabriel Etienne
 Carla Boquimpani
 Ricardo Pasquini
 Richard E. Clark
 Viviane Dubruille
 Ian W. Flinn
 Slawomira Kyrcz-Krzemien
 Ewa Medras
 Maria Zanichelli
 Israel Bendit
 Silvia Cacciatore
 Ksenia Titorenko
 Paola Aimone
 Giuseppe Saglio
 Andreas Hochhaus

Other Contributor(s)

Siriraj Hospital
 South Australian Health and Medical Research Institute
 Section of Hematology Oncology, The University of Chicago
 CHU de Nantes
 Slaski Uniwersytet Medyczny w Katowicach
 Charité – Universitätsmedizin Berlin
 Royal Liverpool University Hospital
 Universitätsklinikum Jena und Medizinische Fakultät
 Sarah Cannon Research Institute
 Universidade Federal do Parana
 University of Texas MD Anderson Cancer Center
 Università degli Studi di Torino
 Novartis International AG
 The University of Adelaide
 Universidade de São Paulo
 Wroclaw Medical University
 Institut Bergonie
 The Catholic University of Korea, College of Medicine
 Novartis Pharma LLC
 Oncoclínica Rio de Janeiro
 Hemorio

Abstract

In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, and increased eligibility for treatment-free remission (TFR). Cumulative 10-year rates of MMR and MR4.5 were higher with nilotinib (300 mg twice daily [BID], 77.7% and 61.0%, respectively; 400 mg BID, 79.7% and 61.2%, respectively) than with imatinib (400 mg once daily [QD], 62.5% and 39.2%, respectively). Cumulative rates of TFR eligibility at 10 years were higher with nilotinib (300 mg BID, 48.6%; 400 mg BID, 47.3%) vs imatinib (29.7%). Estimated 10-year overall survival rates in nilotinib and imatinib arms were 87.6%, 90.3%, and 88.3%, respectively. Overall frequency of adverse events was similar with nilotinib and imatinib. By 10 years, higher cumulative rates of cardiovascular events were reported with nilotinib (300 mg BID, 16.5%; 400 mg BID, 23.5%) vs imatinib (3.6%), including in Framingham low-risk patients. Overall efficacy and safety results support the use of nilotinib 300 mg BID as frontline therapy for optimal long-term outcomes, especially in patients aiming for TFR. The benefit-risk profile in context of individual treatment goals should be carefully assessed.

Keyword(s)

Biochemistry, Genetics and Molecular Biology
 Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/76294

Collections

Scopus 2021